Wednesday, April 22, 2026
29.4 C
Bengaluru

IQVIA Sponsors Race for 7 to Commemorate World Rare Disease Day

#IQVIA Sponsors Race for 7 to commemorate World Rare Disease Day

“IQVIA is delighted to be associated for the fourth consecutive year as the main sponsor of Race for 7. While rare diseases, by virtue of their definition, affect relatively fewer number of patients, the overall number of rare disease patients is large enough to warrant more focused attention.

We hope that the public will come forward in large numbers to participate in Race for 7 and help amplify the voice of the rare disease community. Race for 7 is a unique way of engaging the community with those who matter most – patients and their caregivers for a common cause,” said Amit Mookim, Managing Director, IQVIA – South Asia.

Rare Diseases is a key therapeutic focus for IQVIA who has provided clinical services for more than 258 rare disease studies in 87 countries worldwide since 2011.

Race for 7 is held simultaneously in multiple cities and two countries – India and the USA. Over the years, the run has expanded and in 2019 it will be conducted over February and March across 13 Indian cities – Bengaluru, Mysuru, Chennai, Kolkata, Mumbai, Jaipur, Coimbatore, Bikaner, Hyderabad, New Delhi, Ahmedabad, Thiruvananthapuram, Kochi.

– MedicinMan Press Release

Hot this week

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

Topics

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...
spot_img

Related Articles

spot_imgspot_img